This message contains images. If you don't see images, click here to view.
Advertise in this news brief.




Text Version   RSS   Subscribe   Unsubscribe   Archive   Media Kit June 10, 2015

Home   About   Join Us   Annual Conference   The Voice   Career Center   Resources   Education Plus  

 

HPV vaccine successfully heat stabilized
Vaccine News Daily
According to a recent announcement from Soligenix Inc., the company has successfully applied its heat-stabilization technology to its human papillomavirus vaccine. The company — a late-stage biopharmaceutical company that creates products for the unmet medical needs of patients with biodefense, oncology and inflammation issues — recently published data from its University of Colorado study that demonstrates that the HPV vaccine is now heat stable.
   Share this article:   Share on FacebookTwitterShare on LinkedinE-mail article
READ MORE  


Congratulations to our 2015 cytotechnology graduates!
ASCT
ASCT wishes you the best in your new profession!

Remember to avail yourselves of the ASCT Career Center, a free service that provides access to cytotechnology positions and employers. In addition to posting their resumes, job seekers can browse and view available jobs based on their criteria, and save those jobs for later review if they choose. They can also create a search agent to provide email notifications of jobs that match their criteria.

Share this article:   Share on FacebookTwitterShare on LinkedinE-mail article
READ MORE


UPCOMING EVENTS

Date Event Location More information
July 15,
2015
HPV-related Cancer and Other Practical Aspects of Head and Neck Cytopathology Your PC


William C. Faquin, M.D., Ph.D.
Director, Head and Neck
Massachusetts General Hospital
Associate Professor of Pathology
Harvard Medical Center

More info

Available for 6 months after subscribing

Quality Assessment Center (QAC) Cell Blocks Basics Workbench

Your PC

Details

Available for 6 months after subscribing

Quality Assessment Center (QAC) Document Control for Cytopathology Workbench

Your PC

Details

Available for 6 months after subscribing

Quality Assessment Center (QAC)
The LEAN Cytopathology Laboratory Workbench

Your PC

Details


INDUSTRY NEWS


9-valent human papillomavirus vaccine can potentially reduce cervical cancers by 80 percent
Oncology Nurse Advisor
The newest human papillomavirus vaccine, 9-valent, can potentially prevent 80 percent of cervical cancers in the United States if given to all children at age 11 or 12 years, before they are exposed to the virus. These findings from a seven-center study were published in the Journal of the National Cancer Institute.
Share this article:   Share on FacebookTwitterShare on LinkedinE-mail article
READ MORE


Study shows trophon EPR effective in inactivating high-risk, cancer-causing HPV
News Medical
A new study presented at the Society for Healthcare Epidemiology of America (SHEA) has demonstrated that the trophon EPR is the only high level disinfection system proven to kill natural, infectious, high-risk human papilloma virus under normal use conditions. High-risk HPV accounts for 5 percent of all cancers worldwide and is responsible for almost all cases of cervical cancer and is a leading cause of oral, throat, anal and genital cancers.
Share this article:   Share on FacebookTwitterShare on LinkedinE-mail article
READ MORE


Missed an issue of ASCT Viewpoint? Click here to visit the ASCT Viewpoint archive page.


Persistent HPV 16 in oral rinses signals poor prognosis for HPV-positive oropharyngeal carcinoma
Oncology Nurse Advisor
Although infrequent, detection of human papillomavirus 16 DNA in oral rinses following treatment for HPV-positive oropharyngeal carcinoma "is strongly associated with poor prognosis, highly predictive of recurrence — perhaps more so of local recurrence — and is a potential tool for long-term tumor surveillance," a study concluded at the 2015 American Society of Clinical Oncology Annual Meeting.
Share this article:   Share on FacebookTwitterShare on LinkedinE-mail article
READ MORE


Genticel announces positive results of new multivalent HPV therapeutic vaccine based on Vaxiclase platform
News Medical
Genticel, a French biotechnology company and developer of innovative immunotherapies to prevent cancers caused by the human papillomavirus, announced positive preclinical in vivo proof of concept results of GTL002, its multivalent HPV therapeutic vaccine candidate based on the company's versatile Vaxiclase platform.
Share this article:   Share on FacebookTwitterShare on LinkedinE-mail article
READ MORE


MORE NEWS


Mayo Clinic researchers determine use of high definition optical technology enables physicians to identify precancerous polyps immediately
Dark Daily
High definition optical technology is reaching the point where gastroenterologists are able to identify pre-cancerous polyps with 96 percent accuracy during colonoscopies, according to a recent study conducted at the Mayo Clinic. Pathologists will want to pay close attention to the published findings of this study. That's because GI biopsies represent a significant proportion of specimens referred to anatomic pathologists.
Share this article:   Share on FacebookTwitterShare on LinkedinE-mail article
READ MORE


Researchers hail new cancer treatment: Unlocking the body's immune system
CNN
Researchers meeting in Chicago are hailing what they believe may be a potent new weapon in the fight against cancer: the body's own immune system. An international study found that a combination of two drugs that helped allow the immune system to fight the cancer — ipilimumab and nivolumab — stopped the deadly skin cancer melanoma from advancing for nearly a year in 58 percent of the cases.
Share this article:   Share on FacebookTwitterShare on LinkedinE-mail article
READ MORE


Improving academic lab safety
Safety + Health
More than five years ago, a Texas Tech University graduate student lost three fingers and suffered burns and eye damage when a metal compound detonated during a laboratory project. Meanwhile, the University of California, Los Angeles, has spent $20 million on lab safety following the death of a staff researcher in a lab fire in 2008. The researcher was not wearing a protective lab coat when the plunger on a syringe she was using dislodged, discharging a chemical compound that burns when exposed to air. She suffered serious burns and died nearly three weeks later. These incidents illustrate some of the hazards of lab work.
Share this article:   Share on FacebookTwitterShare on LinkedinE-mail article
READ MORE


 

ASCT Viewpoint
Colby Horton, Vice President of Publishing, 469.420.2601
Download media kit

Esther Cho, Content Editor, 469.420.2671   
Contribute news

This edition of ASCT Viewpoint was sent to ##Email##. To unsubscribe, click here. Did someone forward this edition to you? Subscribe here -- it's free!
Recent issues
May 27, 2015
May 13, 2015
April 22, 2015
April 8, 2015



7701 Las Colinas Ridge, Ste. 800, Irving, TX 75063